← Back to Screener
Kalaris Therapeutics, Inc. Common Stock (KLRS)
Price$6.60
Favorite Metrics
Price vs S&P 500 (26W)33.28%
Price vs S&P 500 (4W)-13.30%
Market Capitalization$132.49M
All Metrics
Book Value / Share (Quarterly)$3.44
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.68
Price vs S&P 500 (YTD)-29.26%
EPS (TTM)$-4.27
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-4.27
EPS (Annual)$-11.78
ROI (Annual)-52.07%
Cash / Share (Quarterly)$5.15
ROA (Last FY)-49.77%
EBITD / Share (TTM)$-2.86
ROE (5Y Avg)-70.78%
Cash Flow / Share (Annual)$-1.68
P/B Ratio1.68x
P/B Ratio (Quarterly)1.79x
Net Income / Employee (Annual)$-10
ROA (TTM)-43.56%
EPS Incl Extra (Annual)$-11.78
Current Ratio (Annual)12.23x
Quick Ratio (Quarterly)12.15x
3-Month Avg Trading Volume0.09M
52-Week Price Return-5.67%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)779.35x
Asset Turnover (Annual)0.00x
52-Week High$11.88
EPS Excl Extra (Annual)$-11.78
CapEx CAGR (5Y)-3.58%
26-Week Price Return42.02%
Quick Ratio (Annual)12.15x
13-Week Price Return-31.60%
Total Debt / Equity (Annual)0.41x
Current Ratio (Quarterly)12.23x
Enterprise Value$66.512
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-14023.53%
Cash / Share (Annual)$5.15
3-Month Return Std Dev94.59%
Net Income / Employee (TTM)$-7
ROE (Last FY)-52.07%
EPS Basic Excl Extra (Annual)$-11.78
Total Debt / Equity (Quarterly)0.41x
EPS Incl Extra (TTM)$-4.27
ROI (TTM)-47.48%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-40.77%
Year-to-Date Return-25.12%
5-Day Price Return0.16%
EPS Normalized (Annual)$-11.78
ROA (5Y Avg)-57.85%
Net Profit Margin (Annual)-14023.53%
Month-to-Date Return9.53%
EBITD / Share (Annual)$-11.78
Operating Margin (Annual)-15705.88%
LT Debt / Equity (Annual)0.41x
ROI (5Y Avg)-70.78%
LT Debt / Equity (Quarterly)0.41x
EPS Basic Excl Extra (TTM)$-4.27
P/B Ratio (Annual)1.79x
Book Value / Share (Annual)$3.44
Price vs S&P 500 (13W)-34.47%
Beta0.29x
P/FCF (Annual)68.29x
Revenue / Share (TTM)$0.00
ROE (TTM)-73.11%
52-Week Low$2.14
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KLRSKalaris Therapeutics, Inc. Common Stock | — | — | — | — | $6.60 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing TH103, a next-generation anti-VEGF therapy for exudative and neovascular retinal diseases. The humanized fusion protein is designed to provide longer-lasting and enhanced anti-VEGF activity compared to existing treatments. The company targets prevalent retinal disease markets with significant unmet patient needs.